c-CRAF Inhibitors
2 drugsAbout c-CRAF
c-CRAF (RAF1) is a serine/threonine kinase in the RAS/MAPK pathway, regulating cell growth, proliferation, differentiation, and survival. Its position in the MAPK pathway makes it a key signaling node.
c-CRAF is a drug development target, particularly in oncology, but there is no genetic evidence data available linking c-CRAF mutations to specific diseases.
c-CRAF is targeted by two FDA-approved small molecule drugs: SORAFENIB TOSYLATE (Viatris) and NEXAVAR (Bayer). These drugs have applications in oncology and other therapeutic areas.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Fibrolamellar Carcinoma with only 2 trials.
- phase2 represents biological uncertainty with 57% completion.
Top Drugs
The c-CRAF drug market is concentrated between Viatris and Bayer.
High market concentration suggests potential entry barriers for new companies.
Drug Modality Landscape
Modalities
Routes of Administration
c-CRAF is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or PROTACs may offer differentiation.
Clinical Trials 396 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 164 | 121 | 33 | 9 | 79% |
| Phase 2 | 168 | 99 | 46 | 22 | 68% |
| Phase 3 | 56 | 35 | 11 | 10 | 76% |
| Phase 4 | 8 | 6 | 2 | 0 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2005 - 2020)
The first c-CRAF drug was approved in 2005, with the most recent in 2020.
The approval timeline suggests a potentially maturing market with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 113 clinical trials targeting c-CRAF.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities